Mir-520b targets PTEN in breast cancer cells and inhibits T cells and NK cells, and transforms macrophages toward the M2 type [81] and inhibits endothelial activation by targeting NF-kB transcription factor P65, and inflammation [82]. This evidence concerns the gene NFKB1 and breast carcinoma.